Gabriele Bellio1, Riccardo Marion2, Fabiola Giudici3, Sara Kus4, Maura Tonutti5, Fabrizio Zanconati6, Marina Bortul7. 1. Department of General Surgery, Azienda Sanitaria Universitaria Integrata di Trieste, Italy. Electronic address: gabrielebellio87@gmail.com. 2. Department of General Surgery, Azienda Sanitaria Universitaria Integrata di Trieste, Italy. 3. Breast Unit, Azienda Sanitaria Universitaria Integrata di Trieste, Italy. 4. Department of Radiology, Azienda Sanitaria Universitaria Integrata di Trieste, Italy. 5. Breast Unit, Azienda Sanitaria Universitaria Integrata di Trieste, Italy; Department of Radiology, Azienda Sanitaria Universitaria Integrata di Trieste, Italy. 6. Breast Unit, Azienda Sanitaria Universitaria Integrata di Trieste, Italy; Department of Histopathology, Azienda Sanitaria Universitaria Integrata di Trieste, Italy. 7. Department of General Surgery, Azienda Sanitaria Universitaria Integrata di Trieste, Italy; Breast Unit, Azienda Sanitaria Universitaria Integrata di Trieste, Italy.
Abstract
BACKGROUND: The introduction of breast screening programs has raised the problem of interval breast cancers (IBC). The aims of this study were to analyze the impact of IBC on the screening program, to compare IBC and screen-detected cancers (SDC), and to identify possible predictors of mortality. PATIENTS AND METHODS: Patients with breast cancer diagnosed during the regional breast screening program between January 2008 and December 2013 at a single center in Italy were included. Demographic, preoperative, and postoperative data were prospectively collected and retrospectively analyzed. RESULTS: Five hundred thirty-four patients were enrolled; 106 women (19.9%) had IBC and 428 women (80.1%) SDC. IBC presented more aggressive features compared to SDC, such as tumor invasiveness (95% vs. 85%; P = .005), tumor size (≥ pT2 37% vs. 21%; P = .001), grade (G3 39% vs. 17%; P < .001), and St Gallen molecular subtype (triple negative 22% vs. 7%; P < .001), resulting in higher distant recurrence rate (8% vs. 2%; P = .009) and worse overall and disease-free survival (P = .03 and P = .001, respectively). Cox multivariate regression analysis identified St Gallen molecular subtype as the only predictor of mortality in patients with breast cancer (P = .03). CONCLUSION: IBC accounted for one-fifth of all breast cancers diagnosed in women who followed the regional screening program. Furthermore, IBC appeared to have more aggressive features compared to SDC, leading to worse survival. These worse survivals depended on St Gallen molecular subtype.
BACKGROUND: The introduction of breast screening programs has raised the problem of interval breast cancers (IBC). The aims of this study were to analyze the impact of IBC on the screening program, to compare IBC and screen-detected cancers (SDC), and to identify possible predictors of mortality. PATIENTS AND METHODS: Patients with breast cancer diagnosed during the regional breast screening program between January 2008 and December 2013 at a single center in Italy were included. Demographic, preoperative, and postoperative data were prospectively collected and retrospectively analyzed. RESULTS: Five hundred thirty-four patients were enrolled; 106 women (19.9%) had IBC and 428 women (80.1%) SDC. IBC presented more aggressive features compared to SDC, such as tumor invasiveness (95% vs. 85%; P = .005), tumor size (≥ pT2 37% vs. 21%; P = .001), grade (G3 39% vs. 17%; P < .001), and St Gallen molecular subtype (triple negative 22% vs. 7%; P < .001), resulting in higher distant recurrence rate (8% vs. 2%; P = .009) and worse overall and disease-free survival (P = .03 and P = .001, respectively). Cox multivariate regression analysis identified St Gallen molecular subtype as the only predictor of mortality in patients with breast cancer (P = .03). CONCLUSION: IBC accounted for one-fifth of all breast cancers diagnosed in women who followed the regional screening program. Furthermore, IBC appeared to have more aggressive features compared to SDC, leading to worse survival. These worse survivals depended on St Gallen molecular subtype.
Authors: Yalei Chen; Laura Susick; Melissa Davis; Jessica Bensenhaver; S David Nathanson; Jessica Burns; Lisa A Newman Journal: JAMA Surg Date: 2020-05-01 Impact factor: 14.766
Authors: Marilina García; Maximino Redondo; Irene Zarcos; Javier Louro; Francisco Rivas-Ruiz; Teresa Téllez; Diego Pérez; Francisco Medina Cano; Kenza Machan; Laia Domingo; Maria Del Mar Vernet; Maria Padilla-Ruiz; Xavier Castells; Maria Sala Journal: Eur J Breast Health Date: 2022-04-01
Authors: Genevieve A Fasano; Solange Bayard; Yalei Chen; Leticia Varella; Tessa Cigler; Jessica Bensenhaver; Rache Simmons; Alexander Swistel; Jennifer Marti; Anne Moore; Eleni Andreopoulou; John Ng; Andrew Brandmaier; Silvia Formenti; Haythem Ali; Melissa Davis; Lisa Newman Journal: Breast Cancer Res Treat Date: 2022-01-13 Impact factor: 4.872
Authors: Jung Sun Lee; Hyun-Ah Kim; Se-Heon Cho; Han-Byoel Lee; Min Ho Park; Joon Jeong; Heung Kyu Park; Minkyung Oh; Onvox Yi Journal: Asian Pac J Cancer Prev Date: 2019-06-01
Authors: Marta Hernández-García; Ana Molina-Barceló; Mercedes Vanaclocha-Espi; Óscar Zurriaga; Beatriz Pérez-Gómez; Nuria Aragonés; Pilar Amiano; Jone M Altzibar; Gemma Castaño-Vinyals; María Sala; María Ederra; Vicente Martín; Inés Gómez-Acebo; Carmen Vidal; Adonina Tardón; Rafael Marcos-Gragera; Marina Pollán; Manolis Kogevinas; Dolores Salas Journal: Cancer Causes Control Date: 2021-11-24 Impact factor: 2.506